Onconetix, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
ONCO$3.58-48.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following documents are filed as exhibits to this Report.
EXHIBIT INDEX
| Incorporated by Reference | ||||
|---|---|---|---|---|
| Exhibit No. | Description | Form | Exhibit | Filing Date |
| 2.1 | Agreement and Plan of Merger, dated July 16, 2025, by and among the Company, Ocuvex, and Onconetix Merger Sub, Inc. | 8-K | 2.1 | July 16, 2025 |
| 2.2 | Form of Termination Agreement effective as of September 24, 2025, by and between the Company and Ocuvex Therapeutics, Inc. | 8-K | 10.4 | September 26, 2025 |
| 3.1 | Amended and Restated Certificate of Incorporation | 8-K | 3.1 | February 24, 2022 |
| 3.2 | Certificate of Amendment, dated April 24, 2023 | 8-K | 3.1 | April 24, 2023 |
| 3.3 | Certificate of Amendment, dated December 21, 2023 | 8-K | 3.1 | December 21, 2023 |
| 3.4 | Certificate of Amendment, dated September 24, 2024 | 8-K | 3.1 | September 24, 2024 |
| 3.5 | Certificate of Amendment, dated June 11, 2025 | 8-K | 3.1 | June 11, 2025 |
| 3.6 | Certificate of Designations authorizing the issuance of the Series C Preferred Stock | 8-K | 3.1 | October 3, 2024 |
| 3.7 | Certificate of Correction to Certificate of Designations authorizing the issuance of the Series C Preferred Stock | 10-Q | 3.7 | June 12, 2025 |
| 3.8 | Fourth Amended and Restated Bylaws of the Company | 8-K | 3.2 | December 21, 2023 |
| 3.9 | Certificate of Designation of Series D Preferred Stock. | 8-K | 3.1 | September 26, 2025 |
| 3.10 | Certificate of Designation of Series E Preferred Stock | 8-K | 3.1 | October 3, 2025 |
| 4.1 | Form of Inducement PIO | 8-K | 4.1 | July 11, 2024 |
| 4.2 | Form of Warrant (Series C) | 8-K | 4.1 | October 3, 2024 |
| 4.3 | Form of Warrant (Series D) | 8-K | 4.1 | September 26, 2025 |
| 4.4 | Form of Warrant (Series E) | 8-K | 4.1 | October 3, 2025 |
| 10.1 | Note, dated February 12, 2025 | 8-K | 10.1 | February 18, 2025 |
| 10.2 | Note, dated May 16, 2025 | 8-K | 10.1 | May 22, 2025 |
| 10.3 | Note, dated June 5, 2025 | 8-K | 10.1 | June 11. 2025 |
| 10.4 | Form of Conversion Price Reduction Consent | 8-K | 10.3 | July 16, 2025 |
| 10.5 | Promissory Note, dated August 6, 2025, by and between Keystone Capital Partners, LLC and the Company | 8-K | 10.1 | August 12, 2025 |
| 10.6 | Amended and Restated Promissory Note, dated August 7, 2025, by and between Veru, Inc. and the Company | 8-K | 10.2 | August 12, 2025 |
| 10.7 | Settlement Agreement and Release, dated September 22, 2025, by and between the Company and Veru, Inc. | 8-K | 10.3 | September 26, 2025 |
| 10.8 | Promissory Note, dated August 28, 2025, by and between Keystone Capital Partners, LLC and the Company | 8-K | 10.1 | September 4, 2025 |
| 10.9 | Promissory Note, dated August 28, 2025, by and between KCP Fund I, LLC and the Company | 8-K | 10.2 | September 4, 2025 |
| 10.10 | Second Amended and Restated Promissory Note, dated August 28, 2025, by and between Veru, Inc. and the Company | 8-K | 10.3 | September 4, 2025 |
| 10.11 | Waiver, dated August 28, 2025, by and between Veru, Inc. and the Company | 8-K | 10.4 | September 4, 2025 |
| 10.12 | License Agreement, dated September 17, 2025, by and between Immunovia AB and Proteomedix AG | 8-K | 10.1 | September 22, 2025 |
| 10.13 | Form of Securities Purchase Agreement dated September 22, 2025 relating to the sale of the Series D Preferred Stock and Warrants | 8-K | 10.1 | September 26, 2025 |
| 10.14 | Form of Registration Rights Agreement dated as of September 22, 2025 relating to the resale of the shares of Common Stock underlying the Series D Preferred Stock and Warrants | 8-K | 10.2 | September 26, 2025 |
| 10.15 | Settlement Agreement and Release, dated September 22, 2025, by and between the Company and Veru, Inc. | 8-K | 10.3 | September 26, 2025 |
| 10.16 | Form of Securities Purchase Agreement dated October 1, 2025 relating to the sale of the Series E Preferred Stock and Warrants | 8-K | 10.1 | October 3, 2025 |
| 10.17 | Form of Registration Rights Agreement dated as of October 1, 2025 relating to the resale of the shares of Common Stock underlying the Series E Preferred Stock and Warrants | 8-K | 10.2 | October 3, 2025 |
| 31* | Certification of the Principal Financial Officer and Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||
| 32** | Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||
| 101.INS* | Inline XBRL Instance Document. | |||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |||
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | |||
| * | Filed herewith. |
|---|
| ** | Furnished herewith. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.